nach oben

Die Innere Medizin

Erschienen in:

01.02.2016 | Zytokine | Schwerpunkt: Tuberkulose

Immunität gegen Mycobacterium tuberculosis

verfasst von: A. Nowag, PD Dr. P. Hartmann

Erschienen in: Die Innere Medizin | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf die Infektion mit Mycobacterium tuberculosis (MTB) folgt eine komplexe Immunantwort, die durch ein distinktes Zusammenspiel von angeborenen und adaptiven Komponenten und Mechanismen des Immunsystems charakterisiert ist. Warum die Immunantwort auf MTB nicht zur anhaltenden Eliminierung der Erreger führt, sondern bestenfalls eine stabile Kontrolle der Infektion im Stadium der latenten Infektion erreicht, ist auch über 100 Jahre nach der Entdeckung von MTB durch Robert Koch noch nicht abschließend geklärt. Diese Übersichtsarbeit stellt einen Paradigmenwechsel vor, der voraussetzt, dass sich MTB in der latenten Phase der Infektion keineswegs in einem Ruhezustand befindet und dass die latente Tuberkulose nicht lediglich einen Zustand der bakteriellen Stase beschreibt, sondern ein dynamisches und immunologisches Äquilibrium darstellt, dessen detailliertes Verständnis für die Entwicklung neuer wirksamer Antibiotika und Vakzinekandidaten unverzichtbar ist.

Bafica A, Scanga CA, Feng CG et al (2005) TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 202:1715–1724PubMedCentralCrossRefPubMed

Banaiee N, Kincaid EZ, Buchwald U et al (2006) Potent inhibition of macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J Immunol 176:3019–3027CrossRefPubMed

Barber DL, Mayer-Barber KD, Antonelli LR et al (2010) Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116:3485–3493PubMedCentralCrossRefPubMed

Behar SM, Martin CJ, Booty MG et al (2011) Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol 4:279–287PubMedCentralCrossRefPubMed

Black GF, Thiel BA, Ota MO et al (2009) Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 16:1203–1212PubMedCentralCrossRefPubMed

Blomgran R, Desvignes L, Briken V et al (2012) Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 11:81–90PubMedCentralCrossRefPubMed

Blomgran R, Ernst JD (2011) Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol 186:7110–7119PubMedCentralCrossRefPubMed

Bold TD, Banaei N, Wolf AJ et al (2011) Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLOS Pathog 7:e1002063PubMedCentralCrossRefPubMed

Brigl M, Brenner MB (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22:817–890CrossRefPubMed

10.

Brooks MN, Rajaram MV, Azad AK et al (2011) NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages. Cell Microbiol 13:402–418PubMedCentralCrossRefPubMed

11.

Chao MC, Rubin EJ (2010) Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol 64:293–311CrossRefPubMed

12.

Cooper AM (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27:393–422PubMedCentralCrossRefPubMed

13.

Cooper AM, Adams LB, Dalton DK et al (2002) IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol 10:221–226CrossRefPubMed

14.

Cooper AM, Magram J, Ferrante J et al (1997) Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med 186:39–45PubMedCentralCrossRefPubMed

15.

Cooper AM, Mayer-Barber KD, Sher A (2011) Role of innate cytokines in mycobacterial infection. Mucosal Immunol 4:252–260PubMedCentralCrossRefPubMed

16.

Court N, Vasseur V, Vacher R et al (2010) Partial redundancy of the pattern recognition receptors, scavenger receptors, and C-type lectins for the long-term control of Mycobacterium tuberculosis infection. J Immunol 184:7057–7070CrossRefPubMed

17.

Davis JM, Ramakrishnan L (2009) The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 136:37–49PubMedCentralCrossRefPubMed

18.

De Libero G, Mori L (2005) Recognition of lipid antigens by T cells. Nat Rev Immunol 5:485–496CrossRefPubMed

19.

Divangahi M, Mostowy S, Coulombe F et al (2008) NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 181:7157–7165CrossRefPubMed

20.

Ernst JD (2012) The immunological life cycle of tuberculosis. Nat Rev Immunol 12:581–591CrossRefPubMed

21.

Feng CG, Jankovic D, Kullberg M et al (2005) Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol 174:4185–4192CrossRefPubMed

22.

Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19:93–129CrossRefPubMed

23.

Ford CB, Lin PL, Chase MR et al (2011) Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43:482–486PubMedCentralCrossRefPubMed

24.

Gallegos AM, Pamer EG, Glickman MS (2008) Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J Exp Med 205:2359–2368PubMedCentralCrossRefPubMed

25.

Gill WP, Harik NS, Whiddon MR et al (2009) A replication clock for Mycobacterium tuberculosis. Nat Med 15:211–214PubMedCentralCrossRefPubMed

26.

Govender L, Abel B, Hughes EJ et al (2010) Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 29:51–57PubMedCentralCrossRefPubMed

27.

Harris J, Keane J (2010) How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 161:1–9PubMedCentralPubMed

28.

Holscher C, Reiling N, Schaible UE et al (2008) Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2, -4 and -9. Eur J Immunol 38:680–694CrossRefPubMed

29.

Ishikawa E, Ishikawa T, Morita YS et al (2009) Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 206:2879–2888PubMedCentralCrossRefPubMed

30.

Jick SS, Lieberman ES, Rahman MU et al (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55:19–26CrossRefPubMed

31.

Kaneko H, Yamada H, Mizuno S et al (1999) Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 79:379–386PubMed

32.

Kasmar AG, van Rhijn I, Cheng TY et al (2011) CD1b tetramers bind alphabeta T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. J Exp Med 208:1741–1747PubMedCentralCrossRefPubMed

33.

Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104CrossRefPubMed

34.

Khader SA, Partida-Sanchez S, Bell G et al (2006) Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 203:1805–1815PubMedCentralCrossRefPubMed

35.

Kumar A, Deshane JS, Crossman DK et al (2008) Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon. J Biol Chem 283:18032–18039PubMedCentralCrossRefPubMed

36.

Kwan CK, Ernst JD (2011) HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 24:351–376PubMedCentralCrossRefPubMed

37.

Lalvani A, Brookes R, Wilkinson RJ et al (1998) Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 95:270–275PubMedCentralCrossRefPubMed

38.

Lillebaek T, Dirksen A, Vynnycky E et al (2003) Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis 188:1032–1039CrossRefPubMed

39.

Lin PL, Myers A, Smith L et al (2010) Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 62:340–350PubMedCentralCrossRefPubMed

40.

Marakalala MJ, Guler R, Matika L et al (2011) The Syk/CARD9-coupled receptor Dectin-1 is not required for host resistance to Mycobacterium tuberculosis in mice. Microbes Infect 13:198–201PubMedCentralCrossRefPubMed

41.

Mayer-Barber KD, Andrade BB, Barber DL et al (2011) Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35:1023–1034PubMedCentralCrossRefPubMed

42.

McNab FW, Berry MP, Graham CM et al (2011) Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol 41:1941–1947PubMedCentralCrossRefPubMed

43.

Mishra BB, Moura-Alves P, Sonawane A et al (2010) Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol 12:1046–1063CrossRefPubMed

44.

Moody DB, Young DC, Cheng TY et al (2004) T cell activation by lipopeptide antigens. Science 303:527–531CrossRefPubMed

45.

Newton SM, Smith RJ, Wilkinson KA et al (2006) A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc Natl Acad Sci U S A 103:15594–15598PubMedCentralCrossRefPubMed

46.

North RJ, Jung YJ (2004) Immunity to tuberculosis. Annu Rev Immunol 22:599–623CrossRefPubMed

47.

O’Garra A, Redford PS, McNab FW et al (2013) The immune response in tuberculosis. Annu Rev Immunol 31:475–527CrossRefPubMed

48.

Orme IM, Andersen P, Boom WH (1993) T cell response to Mycobacterium tuberculosis. J Infect Dis 167:1481–1497CrossRefPubMed

49.

Redford PS, Boonstra A, Read S et al (2010) Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 40:2200–2210PubMedCentralCrossRefPubMed

50.

Redford PS, Murray PJ, O’Garra A (2011) The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 4:261–270CrossRefPubMed

51.

Rogerson BJ, Jung YJ, LaCourse R et al (2006) Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology 118:195–201PubMedCentralCrossRefPubMed

52.

Rothfuchs AG, Bafica A, Feng CG et al (2007) Dectin-1 interaction with Mycobacterium tuberculosis leads to enhanced IL-12p40 production by splenic dendritic cells. J Immunol 179:3463–3471CrossRefPubMed

53.

Russell-Goldman E, Xu J, Wang X et al (2008) A Mycobacterium tuberculosis Rpf double-knockout strain exhibits profound defects in reactivation from chronic tuberculosis and innate immunity phenotypes. Infect Immun 76:4269–4281PubMedCentralCrossRefPubMed

54.

Saraiva M, O’Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170–181CrossRefPubMed

55.

Schoenen H, Bodendorfer B, Hitchens K et al (2010) Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 184:2756–2760PubMedCentralCrossRefPubMed

56.

Seung KJ, Bai GH, Kim SJ et al (2003) The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis 7:912–919PubMed

57.

Shafiani S, Tucker-Heard G, Kariyone A et al (2010) Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 207:1409–1420PubMedCentralCrossRefPubMed

58.

Shi L, North R, Gennaro ML (2004) Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung. Infect Immun 72:2420–2424PubMedCentralCrossRefPubMed

59.

Tailleux L, Schwartz O, Herrmann JL et al (2003) DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med 197:121–127PubMedCentralCrossRefPubMed

60.

Tanne A, Ma B, Boudou F et al (2009) A murine DC-SIGN homologue contributes to early host defense against Mycobacterium tuberculosis. J Exp Med 206:2205–2220PubMedCentralCrossRefPubMed

61.

Tsao TC, Huang CC, Chiou WK et al (2002) Levels of interferon-gamma and interleukin-2 receptor-alpha for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 6:720–727PubMed

62.

Tufariello JM, Mi K, Xu J et al (2006) Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis. Infect Immun 74:2985–2995PubMedCentralCrossRefPubMed

63.

Urdahl KB, Shafiani S, Ernst JD (2011) Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 4:288–293PubMedCentralCrossRefPubMed

64.

Vankayalapati R, Wizel B, Weis SE et al (2003) Serum cytokine concentrations do not parallel Mycobacterium tuberculosis-induced cytokine production in patients with tuberculosis. Clin Infect Dis 36:24–28CrossRefPubMed

65.

Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452CrossRefPubMed

66.

Verbon A, Juffermans N, Van Deventer SJ et al (1999) Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 115:110–113PubMedCentralCrossRefPubMed

67.

Voskuil MI, Schnappinger D, Visconti KC et al (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198:705–713PubMedCentralCrossRefPubMed

Titel: Immunität gegen Mycobacterium tuberculosis
verfasst von: A. Nowag
PD Dr. P. Hartmann
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Zytokine
Tuberkulose
Tuberkulose
Mycobacterium tuberculosis
Erschienen in: Die Innere Medizin / Ausgabe 2/2016
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-015-0016-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Immunität gegen Mycobacterium tuberculosis

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Mitteilungen des BDI

Medikamentenresistente Tuberkulose

Mitteilungen des BDI

Bronchoskopische Lungenvolumenreduktion

Mitteilungen der DGIM

Standardtherapie der Tuberkulose

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin